Latest news
Alteogen Signs Up to $365 Million Hybrozyme Licensing Deal for Subcutaneous Biologic - BioPharma APACBioPharma APAC · Fri, 07 Aug 2026 01:06:22 GMTAlteogen signs up to $365 million licensing deal for Hybrozyme drug delivery technology - Indian Pharma PostIndian Pharma Post · Thu, 06 Aug 2026 13:00:00 GMTAlteogen Licenses Subcutaneous Platform to Undisclosed Global Pharma Company in Deal Worth Up to $365 Million - BioPharm InternationalBioPharm International · Wed, 05 Aug 2026 19:10:58 GMTAlteogen Announces Exclusive License Agreement with a Global Pharmaceutical Company for the Development and Commercialization of a Hybrozyme™-Enabled Subcutaneous Biologic Product - Yahoo FinanceYahoo Finance · Wed, 05 Aug 2026 12:00:00 GMTAlteogen licenses SC platform to global pharma in $365 million deal - CHOSUNBIZ - ChosunbizChosunbiz · Tue, 04 Aug 2026 23:37:00 GMT